Systemic sclerosis prevalence and comorbidities in the US, 2001-2002

Current Medical Research and Opinion

Volumn 24, Issue 4, 2008, Pages 1157-1166

  Robinson Jr , Don ^a   Eisenberg, Debra ^b   Nietert, Paul J ^c   Doyle, Mittie ^d   Bala, Mohan ^e   Paramore, Clark ^f   Fraeman, Kathy ^f   Renahan, Kevin ^d  

^a Johnson and Johnson Pharmaceutical Services   (United States)

^b HEALTHCORE INC   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d CENTOCOR INC   (United States)

^e GLAXOSMITHKLINE   (United States)

^f UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Autoimmune disease; Comorbidity; Epidemiology; Prevalence; Scleroderma; Systemic sclerosis

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DISEASE SEVERITY; ENTERITIS; FEMALE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; MEDICAL RECORD; MENTAL DISEASE; MULTIPLE SCLEROSIS; POPULATION MODEL; PREVALENCE; RISK FACTOR; SCORING SYSTEM; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; STATISTICS; SYSTEMIC SCLEROSIS; UNITED STATES;

AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; COMORBIDITY; HUMANS; INFLAMMATORY BOWEL DISEASES; INSURANCE CLAIM REVIEW; MIDDLE AGED; MULTIPLE SCLEROSIS; PREVALENCE; RISK; SCLERODERMA, SYSTEMIC; UNITED STATES;

EID: 42549096220     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X280617     Document Type: Article

References (42)

1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367: 1683-91
2. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003;29:239-54
3. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005;129:819-26
4. Williams JP, Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care 2002;8(21 Suppl):S664-81; quiz S82-5
5. Clements PJ, Becvar R, Drosos AA, et al. Assessment of gastrointestinal involvement. Clin Exp Rheumatol 2003;21(3 Suppl 29):S15-18
6. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev 2003;2:119-25
7. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-50
8. McGlynn E. Exploring Policy Issues in Managed Care: Six Illustrative Case Studies. RAND Corporation, 2001
9. Schlesinger M, Druss B, Thomas T. No exit? The effect of health status on dissatisfaction and disenrollment from health plans. Health Serv Res 1999;34:547-76
10. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005;52:2415-24
11. Nietert PJ, Silverstein MD, Silver RM. Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis. J Rheumatol 2001;28:2031-7
12. Robinson D, Jr., Hackett M, Wong J, Kimball AB, Cohen R, Bala M. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin 2006;22:989-1000
13. Wallace DJ, Hahn BH, eds. Dubois' Lupus Erythematosus, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2002
14. Sloka S. Observations on recent studies showing increased co-occurrence of autoimmune diseases. J Autoimmun 2002; 18:251-7
15. Rector TS, Wickstrom SL, Shah M, et al. Specificity and sensitivity of claims-based algorithms for identifying members of Medicare+Choice health plans that have chronic medical conditions. Health Serv Res 2004;39(6 Pt 1):1839-57
16. Woodward M. Epidemiology: Study Design and Data Analysis, 1st edn. Boca Raton: Chapman & Hall, 1999
17. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690-1
18. Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003;41:84-99
19. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27
20. Southern DA, Quan H, Ghali WA. Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care 2004;42:355-60
21. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006;33:1113-16
22. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003;62:728-31
23. Thompson AE, Pope JE. Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. J Rheumatol 2002;29:1867-73
24. Chung L, Krishnan E, Chakravarty EF. Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. Rheumatology (Oxford) 2007;46:1808-13
25. Fleischmann RM. Is there a need for new therapies for rheumatoid arthritis? J Rheumatol Suppl 2005;73:3-7; discussion 29-30
26. Nietert PJ, Silver RM, Mitchell HC, et al. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol 2005;32:1888-92
27. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2-10
28. Kiyota Y, Schneeweiss S, Glynn RJ, et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004;148:99-104
29. Goff DC, Jr., Pandey DK, Chan FA, et al. Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med 2000;160:197-202
30. Strom BL. Data validity issues in using claims data. Pharmacoepidemiol Drug Saf 2001;10:389-92
31. Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum 2005;34:714-20
32. Allcock RJ, Forrest I, Corris PA, et al. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 2004;43:596-602
33. Le Guern V, Mahr A, Mouthon L, et al. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford) 2004;43:1129-37
34. Feghali-Bostwick C, Medsger TA, Jr., Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003;48:1956-63
35. Furst DE, Khanna D, Mattucci-Cerinic M, et al. Scleroderma -developing measures of response. J Rheumatol 2005;32:2477-80
36. Garabrant DH, Lacey JV, Jr., Laing TJ, et al. Scleroderma and solvent exposure among women. Am J Epidemiol 2003;157:493-500
37. Khanna D, Furst DE, Clements PJ, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832-40
38. Maitre A, Hours M, Bonneterre V, et al. Systemic sclerosis and occupational risk factors: role of solvents and cleaning products. J Rheumatol 2004;31:2395-401
39. Nordenbaek C, Johansen JS, Halberg P, et al. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol 2005;34:293-7
40. Magnant J, de Monte M, Guilmot JL, et al. Relationship between occupational risk factors and severity markers of systemic sclerosis. J Rheumatol 2005;32:1713-8
41. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42
42. Sultan N, Pope JE, Clements PJ. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. Rheumatology (Oxford) 2004;43:472-8